Recruiting
Phase 2

Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease

Sponsor:

Alkeus Pharmaceuticals, Inc.

Code:

NCT02402660

Conditions

Stargardt Disease

Stargardt Macular Degeneration

Stargardt Macular Dystrophy

Autosomal Recessive Stargardt Disease 1 (ABCA4-related)

Eligibility Criteria

Sex: All

Age: 8 - 70

Healthy Volunteers: Not accepted

Interventions

ALK-001

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information